Published on 5 Feb 2024 on GuruFocus.com via Yahoo Finance
Mesa Laboratories Inc (MLAB) Faces Revenue Dip Amidst Strategic Acquisitions
Revenue: Reported a slight decrease of 1.5% year-over-year to $53,473 thousand.Net Income: Experienced a significant increase of 369% to $2,116 thousand.Adjusted Operating Income (AOI): Non-GAAP AOI, excluding unusual items, decreased by 6.8% to $11,981 thousand.Gross Profit Percentage: Improved by 210 basis points compared to the same quarter last year.Division Performance: Calibration Solutions division showed robust growth, while other divisions faced declines.Acquisitions: GKE acquisition expected to fully benefit in the upcoming quarter.Stock Performance: Earnings per diluted share increased to $0.39 from $0.08 year-over-year.
Warning! GuruFocus has detected 7 Warning Signs with MLAB.
Mesa Laboratories Inc (NASDAQ:MLAB) released its 8-K filing on February 5, 2024, detailing the financial results for the third fiscal quarter ended December 31, 2023. The company, a global leader in life science tools and critical quality control solutions, operates across four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics, serving both the United States and international markets.